The DOI matches its Crossref record.
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus
Open accessAbstract
Mutations in the flqA (formerly ofx/cfx) resistance locus of Staphylococcus aureus were previously shown to be common after first-step selections for resistance to ciprofloxacin and ofloxacin and to map on the S. aureus chromosome distinctly from gyrA, gyrB, and norA.grlA and grlB, the genes for the topoisomerase IV of S. aureus, were identified from a genomic lambda library on a common KpnI fragment, and grlB hybridized specifically with the chromosomal SmaI A fragment, which contains the flqA locus. Amplification of grlA sequences (codons 1 to 251) by PCRs from nine independent single-step flqA mutants, one multistep mutant, and the parent strain identified mutations encoding a change from Ser to Phe at position 80 in four mutants, a novel change from Ala to either Glu or Pro at position 116 in three mutants, and no change in three mutants. In the multistep mutant, another resistance locus, flqC, was mapped by transformation to the chromosomal SmaI G fragment by linkage to omega(ch::Tn551)1051 (58%) and nov (97.9%), which encodes resistance to novobiocin. This fragment contains the gyrA gene, and flqC mutants had a mutation in gyrA encoding a change from Ser to Leu at position 84, a change previously found in resistant clinical isolates. In genetic outcrosses, the flqC (gyrA) mutation expressed resistance only in flqA mutants, including those with both types of grla mutations. The silent mutant allele of gyrA was present in a flqA background and expressed resistance only upon introduction of a grlA mutation. At fourfold the MIC of ciprofloxacin, the bactericidal activity of ciprofloxacin was reduced in a grlA mutant and was abolished in gyrA grlA double mutants. These findings provide direct genetic evidence that topoisomerase IV is the primary target of current fluoroquinolones in S. aureus and that this effect may result from the greater sensitivity of topoisomerase IV relative to that of DNA gyrase to these agents. Furthermore, resistance from an altered DNA gyrase requires resistant topoisomerase IV for its expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica, K., & Zhao, X. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.3.377-392.1997 · Cited by 1,494
Antimicrobial resistance: the example of Staphylococcus aureus
Lowy, F. D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18535 · Cited by 1,445
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications
Chambers, H. F. (1997) · Clinical Microbiology Reviews · doi:10.1128/cmr.10.4.781 · Cited by 1,127
Mechanisms of Resistance to Quinolones
Jacoby, G. A. (2005) · Clinical Infectious Diseases · doi:10.1086/428052 · Cited by 924
Mechanisms of drug resistance: quinolone resistance
Hooper, D. C., & Jacoby, G. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12830 · Cited by 716
Self-citationRuiz, J. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg222 · Cited by 711
Emerging Mechanisms of Fluoroquinolone Resistance
Hooper, D. C. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010239 · Cited by 633
Self-citationQuinolones: from antibiotics to autoinducers
Heeb, S., Fletcher, M. P., Chhabra, S. R., Diggle, S. P., Williams, P., & Cámara, M. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2010.00247.x · Cited by 595
Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance
Hooper, D. C., & Jacoby, G. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025320 · Cited by 553
Self-citationMechanisms of Action of Antimicrobials: Focus on Fluoroquinolones
Hooper, D. C. (2001) · Clinical Infectious Diseases · doi:10.1086/319370 · Cited by 517
Self-citationMechanisms of fluoroquinolone resistance
Hooper, D. C. (1999) · Drug Resistance Updates · doi:10.1054/drup.1998.0068 · Cited by 488
Self-citationThe mutant selection window and antimicrobial resistance
Drlica, K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg269 · Cited by 437
Bacterial resistance to antibiotics: Modified target sites
LAMBERT, P. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.04.003 · Cited by 424
Multidrug Efflux Pumps in Staphylococcus aureus: an Update
Costa, S. S., Viveiros, M., Amaral, L., & Couto, I. (2013) · The Open Microbiology Journal · doi:10.2174/1874285801307010059 · Cited by 409
Mechanisms of Action and Resistance of Older and Newer Fluoroquinolones
Hooper, D. C. (2000) · Clinical Infectious Diseases · doi:10.1086/314056 · Cited by 409
Self-citationFluoroquinolone resistance among Gram-positive cocci
Hooper, D. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00369-9 · Cited by 320
Self-citationFluoroquinolones: Action and Resistance
Drlica, K., & Malik, M. (2003) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026033452537 · Cited by 317
Blondeau, J. M., Zhao, X., Hansen, G., & Drlica, K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.433-438.2001 · Cited by 314
Multi-targeting by monotherapeutic antibacterials
Silver, L. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2202 · Cited by 311
Plasmid-mediated quinolone resistance: an update
Rodríguez-Martínez, J. M., Velasco, C., Pascual, Á., Cano, M. E., Martínez-Martínez, L., Martínez-Martínez, L., & Pascual, Á. (2011) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-010-0120-2 · Cited by 306
Mode of Action of Fluoroquinolones
Hooper, D. C. (1999) · Drugs · doi:10.2165/00003495-199958002-00002 · Cited by 290
Self-citationAntibiotic Resistance in Bacteria and Its Future for Novel Antibiotic Development
YONEYAMA, H., & KATSUMATA, R. (2006) · Bioscience, Biotechnology, and Biochemistry · doi:10.1271/bbb.70.1060 · Cited by 286
Dong, Y., Zhao, X., Domagala, J., & Drlica, K. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1756 · Cited by 278
Metadata
- Authors
- Ng, E. Y., Trucksis, M., & Hooper, D. C.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1996-08
- Volume
- 40
- Issue
- 8
- Pages
- 1881-1888
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2131012394
- Cited by
- 232
- References
- 0
- FWCI
- 22.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.